Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 23;80(11):1419–1428. doi: 10.1136/annrheumdis-2021-220263

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Disease outcomes at month 6 (A) observed percentages*; (B) PS-adjusted ORs (95% CI) of ustekinumab versus TNFi outcomes. *Observed percentages including non-responder imputation of patients who stopped or switched initial treatment. †cDAPSA remission ≤4. ‡Including remission; cDAPSA ≤13. §Including VLDA. cDAPSA, clinical Disease Activity Index for Psoriatic Arthritis; LDA, low disease activity; MDA, minimal disease activity; PS, propensity score; TNFi, tumour necrosis factor inhibitor; UST, ustekinumab; VLDA, very low disease activity.